253 related articles for article (PubMed ID: 31846168)
1. Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: A United Kingdom Haemophilia Centre Doctors' Organisation guideline.
Gray E; Kitchen S; Bowyer A; Chowdary P; Jenkins PV; Murphy P; Platton S; Riddell A; Lester W
Haemophilia; 2020 Jan; 26(1):6-16. PubMed ID: 31846168
[TBL] [Abstract][Full Text] [Related]
2. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline.
Jenkins PV; Bowyer A; Burgess C; Gray E; Kitchen S; Murphy P; Platton S; Riddell A; Chowdary P; Lester W
Haemophilia; 2020 Jan; 26(1):151-155. PubMed ID: 31859415
[TBL] [Abstract][Full Text] [Related]
3. Summary of the WHO hearing on the development of product-specific reference materials for coagulation factor VIII and factor IX products.
Ovanesov MV; Williams SC; Nübling CM; Dodt J; Hilger A; Maryuningsih Y; Gray E
Biologicals; 2020 Sep; 67():88-93. PubMed ID: 32847723
[TBL] [Abstract][Full Text] [Related]
4. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
[TBL] [Abstract][Full Text] [Related]
5. Laboratory coagulation tests and recombinant porcine factor VIII: A United Kingdom Haemophilia Centre Doctors' Organisation guideline.
Bowyer A; Gray E; Lowe A; Murphy P; Platton S; Riddell A; Chowdary P; Lester W; Jenkins PV
Haemophilia; 2022 May; 28(3):515-519. PubMed ID: 35279922
[TBL] [Abstract][Full Text] [Related]
6. New products for the treatment of haemophilia.
Laffan M
Br J Haematol; 2016 Jan; 172(1):23-31. PubMed ID: 26456702
[TBL] [Abstract][Full Text] [Related]
7. Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management.
Müller J; Goldmann G; Marquardt N; Pötzsch B; Oldenburg J
Hamostaseologie; 2020 Nov; 40(S 01):S15-S20. PubMed ID: 33187006
[TBL] [Abstract][Full Text] [Related]
8. UK Haemophilia Centre Doctors' Organisation guidance on the use of extended-half-life coagulation factor concentrates in routine clinical practice: Report of a meeting on their adoption by Belgian haemophilia treaters.
Hermans C; Van Damme A; Dolan G; Maes P; Peerlinck K
Haemophilia; 2018 Sep; 24(5):e378-e380. PubMed ID: 30182454
[No Abstract] [Full Text] [Related]
9. Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B.
Marlar RA; Strandberg K; Shima M; Adcock DM
Eur J Haematol; 2020 Jan; 104(1):3-14. PubMed ID: 31606899
[TBL] [Abstract][Full Text] [Related]
10. Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
Jeanpierre E; Pouplard C; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Stepina N; Toulon P; Voisin S; Ternisien C; Nougier C;
Eur J Haematol; 2020 Aug; 105(2):103-115. PubMed ID: 32277501
[TBL] [Abstract][Full Text] [Related]
11. Factor Activity Assays for Monitoring Extended Half-Life FVIII and Factor IX Replacement Therapies.
Kitchen S; Tiefenbacher S; Gosselin R
Semin Thromb Hemost; 2017 Apr; 43(3):331-337. PubMed ID: 28264199
[TBL] [Abstract][Full Text] [Related]
12. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
[TBL] [Abstract][Full Text] [Related]
13. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
[TBL] [Abstract][Full Text] [Related]
14. An Update on Laboratory Diagnostics in Haemophilia A and B.
Müller J; Miesbach W; Prüller F; Siegemund T; Scholz U; Sachs UJ;
Hamostaseologie; 2022 Aug; 42(4):248-260. PubMed ID: 35104901
[TBL] [Abstract][Full Text] [Related]
15. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders.
United Kingdom Haemophelia Centre Doctors' Organisation
Haemophilia; 2003 Jan; 9(1):1-23. PubMed ID: 12558775
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of chromogenic assays for potency assignment and recovery of plasma-derived FVIII and FIX concentrates or their recombinant long acting therapeutic equivalents with potential application in treated pediatric hemophiliac patients.
Amiral J; Seghatchian J
Transfus Apher Sci; 2018 Jun; 57(3):363-369. PubMed ID: 29895509
[TBL] [Abstract][Full Text] [Related]
17. The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation.
Brennan Y; Parikh S; McRae S; Tran H
Haemophilia; 2020 May; 26(3):529-535. PubMed ID: 32243027
[TBL] [Abstract][Full Text] [Related]
18. New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacement.
Van den Bossche D; Peerlinck K; Jacquemin M
Int J Lab Hematol; 2018 May; 40 Suppl 1():21-29. PubMed ID: 29741261
[TBL] [Abstract][Full Text] [Related]
19. Real-life experience in switching to new extended half-life products at European haemophilia centres.
Peyvandi F; Garagiola I; Boscarino M; Ryan A; Hermans C; Makris M
Haemophilia; 2019 Nov; 25(6):946-952. PubMed ID: 31418967
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
[No Abstract] [Full Text] [Related]
[Next] [New Search]
